Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
OnKure Therapeutics (OKUR)
NASDAQ:OKUR
Holding OKUR?
Track your performance easily
See the Price Targets and Ratings of:
OKUR Analyst Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
OKUR Stock 12 Month Forecast
Average Price Target
$35.33
▲(120.95% Upside)
| Highest Price Target$40.00 | Average Price Target$35.33 | Lowest Price Target$31.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
Reiterated
11/11/24
H.C. Wainwright
Reiterated
11/08/24
Oppenheimer
Initiated
10/10/24
Leerink Partners
$10
Hold
-37.46%
Downside
Reiterated
05/07/24
Maintaining Hold on Reneo Pharmaceuticals Amidst Strategic Uncertainties and Pipeline Setbacks
Bank of America Securities
$12
Sell
-24.95%
Downside
Reiterated
03/28/24
Sell Rating on Reneo Pharmaceuticals Amid Strategic Uncertainty and Reduced Price Target
Jefferies
$170→$18
Hold
12.57%
Upside
Downgraded
12/15/23
Reneo Pharmaceuticals just downgraded at Jefferies, here's whyReneo Pharmaceuticals just downgraded at Jefferies, here's why
Ladenburg Thalmann & Co.
―
Hold
―
Downgraded
12/14/23
Reneo Pharmaceuticals just downgraded at Ladenburg, here's whyReneo Pharmaceuticals just downgraded at Ladenburg, here's why
Piper Sandler
$40
Hold
150.16%
Upside
Downgraded
12/14/23
Piper Sandler downgrades Reneo Pharmaceuticals (RPHM) to NeutralPiper Sandler analyst Yasmeen Rahimi downgraded Reneo Pharmaceuticals (NASDAQ: RPHM) from Overweight to Neutral with a price target of $4.00 (from $25.00).
Robert W. Baird
$30
Hold
87.62%
Upside
Downgraded
12/14/23
Analysts Offer Insights on Healthcare Companies: Rain Therapeutics (NASDAQ: RAIN), Reneo Pharmaceuticals (NASDAQ: RPHM) and Bicycle Therapeutics (NASDAQ: BCYC)
Best Analysts Covering OnKure Therapeutics
Which Analyst Should I Follow If I Want to Buy OKUR and Sell After:
1 Month
xxx
Success Rate
1/4 ratings generated profit
Average Return
-8.60%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 25.00% of your transactions generating a profit, with an average return of -8.60% per trade.
3 Months
xxx
Success Rate
2/4 ratings generated profit
Average Return
-21.02%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -21.02% per trade.
1 Year
Success Rate
1/4 ratings generated profit
Average Return
-44.60%
reiterated a sell rating 8 months ago
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -44.60% per trade.
2 Years
xxx
Success Rate
1/4 ratings generated profit
Average Return
-44.60%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of -44.60% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
OKUR Analyst Recommendation Trends
Rating
Dec 23
Mar 24
May 24
Oct 24
Nov 24
Strong Buy
3
3
0
3
5
Buy
6
0
0
0
0
Hold
8
9
11
3
2
Sell
1
2
2
1
0
Strong Sell
0
0
0
0
0
total
18
14
13
7
7
Each month's total comprises the sum of three months' worth of ratings.
OKUR Financial Forecast
OKUR Stock Forecast FAQ
What is OKUR’s average 12-month price target, according to analysts?
Based on analyst ratings, OnKure Therapeutics’s 12-month average price target is $35.33.
What is OKUR’s upside potential, based on the analysts’ average price target?
OnKure Therapeutics has 120.95% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is OKUR a Buy, Sell or Hold?
OnKure Therapeutics has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
What is OnKure Therapeutics’s price target?
The average price target for OnKure Therapeutics is $35.33. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $31.00. The average price target represents 120.95% Increase from the current price of $15.99.
The highest analyst price target is $40.00 ,the lowest forecast is $31.00. The average price target represents 120.95% Increase from the current price of $15.99.
What do analysts say about OnKure Therapeutics?
OnKure Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of OKUR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.